Development: VGV-X: HIV/AIDS

Six international, human clinical trials found that our first-generation HIV/AIDS drug compound significantly reduced the viral load by over 90-95% in some patients. That therapy led to the development of a second generation TPT drug compound called VGV-X. We believe that VGV-X may address the reason that our first HIV/AIDS drug reduced the viral load in some patients, but not others. Preparing this therapeutic approach for human clinical trials is a top priority.

Current antiviral treatments for HIV and AIDS are drug combinations that are expensive, difficult to access in many areas of the world, and accompanied by a number of complications, including moderate to severe side effects, onerous dosing regimens, multiple drug interactions, and the development of drug resistant strains of the HIV virus. Based on our experience with an earlier version of VGV-X, we are hopeful that it will continue to demonstrate only moderate side effects and a less onerous dosing regimen.

With over 40 million cases of HIV in the world and growing, including over 25 million in Sub-Saharan Africa alone, we believe that such a therapy would be of significant interest.